Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Methylnaltrexone Stories

2013-11-19 08:27:33

SAN FRANCISCO, Nov. 19, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA), which has been studied in opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, the most common side effect( )caused by chronic...

2013-09-30 08:28:25

SAN FRANCISCO, Sept. 30, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that AstraZeneca announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for Naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist, which has been specifically designed for the treatment of opioid-induced constipation (OIC) for adult patients 18 years and older, including patients with inadequate response to...

2013-08-27 23:29:33

Achieve Clinical Research is conducting a randomized clinical study to evaluate the safety, tolerability, and efficacy of a new drug for the treatment of opioid-induced constipation in adults taking opioid therapy for chronic non-cancer pain. Birmingham, Alabama (PRWEB) August 27, 2013 *To see if you qualify for this Constipation Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com) or contact us directly at (205) 380-6434. There is no cost...

2013-06-04 08:30:17

Poster Presentation to Highlight KP201's Unique Abuse-Deterrent Properties and Its Potential to Prevent or Reduce Opioid-Induced Constipation NORTH LIBERTY, Iowa, June 4, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that that its Vice President of Research, Sven Guenther, Ph.D., will present a poster on the Company's novel pain drug candidate, KP201, at...

2012-12-17 08:25:53

GAITHERSBURG, Md., Dec. 17, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, announced that it has signed an in-licensing agreement with Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) for Progenics' Clostridium difficile late-stage preclinical program. The agreement was led by MedImmune's Infectious Diseases & Vaccines Innovative Medicines (iMed) Unit. Clostridium difficile infections are the leading cause of hospital-acquired bacterial infections in the U.S. and...

2012-11-12 08:26:39

SAN FRANCISCO, Nov. 12, 2012 /PRNewswire/ -- AstraZeneca today announced positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related pain and opioid-induced constipation (OIC). These Phase III KODIAC trials evaluated the safety and efficacy of naloxegol, an oral peripherally-acting, mu-opioid receptor antagonist for the treatment of OIC, a common side effect of prescription opioids. KODIAC-04 and -05 are both multicenter, randomized,...

2012-06-07 02:28:09

SAN FRANCISCO, June 7, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that the U.S. Food and Drug Administration (FDA) has designated NKTR-181 as a Fast Track development program for the treatment of moderate to severe chronic pain. NKTR-181 is a novel mu-opioid agonist molecule, which is designed to have a slow rate of entry into the brain to reduce the attractiveness of the molecule as a target of abuse and to reduce its CNS-mediated side effects. NKTR-181 was...

2012-03-27 05:16:05

(Ivanhoe Newswire) -- Opioid-based painkillers, such as morphine, have been the standard treatment of postoperative and chronic cancer pain for over 200 years. Two new studies show that opioid drugs may stimulate the spread and growth of tumors! "Epidemiologic findings suggest that the type of anesthesia we do for cancer surgery influences recurrence rate, and laboratory studies demonstrate that opioids influence tumor progression and metastasis. These studies have caused anesthesiologists...

2012-03-21 10:30:33

Opioid drugs used to relieve pain in postoperative and chronic cancer patients may stimulate the growth and spread of tumors, according to two studies and a commentary in the 2012 annual Journal Symposium issue of Anesthesiology, the academic journal of the American Society of Anesthesiologists. "Epidemiologic findings suggest that the type of anesthesia we do for cancer surgery influences recurrence rate, and laboratory studies demonstrate that opioids influence tumor progression and...